September 2017 ARTICLE LIST >>
PharmaTutor (September - 2017)
ISSN: 2347 - 7881
(Volume 5, Issue 9)
Received On: 04/05/2017; Accepted On: 19/05/2017; Published On: 01/09/2017
AUTHORS:
M.S.Umashankar*, K.S.Lakshmi, A.Bharath Kumar, A.Porselvi
SRM College of Pharmacy,
SRM University, Kattankulathur, Tamil Nadu, India
*abharatpharma@gmail.com
ABSTRACT:
It is a critical clinical condition in which more abnormalities in cardiac structure and its functions may impact the ineffectiveness of the heart to supply required oxygen to meet the cellular metabolic demands of the body. Heart is covered with protective layers and express the various functions in the body. Clinically cardiac disease prevalence rises with individual age. Cardiac dysfunction happens because of changes in blood volume, and neurohumoral transmission status. These desirable mechanisms to maintain adequate cardiac output and arterial blood pressure. The neurohumoral responses act as compensatory mechanisms and provokes heart failure by increasing ventricular after load and increasing preload,which further elevates the cardiac failure. Health care system with a clinical pharmacist is well allocated to impact the disease management through identification of risk factors, stage of severity, educating the patients and health care practioners and implementing the awareness programmes, modification of life style interventions with in health care system beneficial to the community may reduce the progression of disease severity.
How to cite this article: Umashankar MS, Lakshmi KS, Kumar AB, Porselvi A;Clinical Pharmacist specialized care in Management of Congestive Heart Failure - A Brief Review; PharmaTutor; 2017; 5(9); 16-22
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Hobbs FDR. The scale of heart failure: diagnosis and management issues for primary care. Heart. 1999;82(Suppl. IV):8–10.
2. Mahoney JS. An ethnographic approach to understanding the illness experiences of patients with congestive heart failure and their family members. Heart Lung. 2001;30:429–36.
3. Sullivan MJ, Hawthorne MH. Nonpharmacological interventions in the treatment of heart failure. J Cardiovasc Nurs. 1996;10:47–57.
4. Carlson B, Riegel B, Faan C, Moser D. Self-care abilities of patients with heart failure. Heart Lung. 2001;30:351–9.
5. Zannad F. Evidence-based drug therapy for chronic heart failure. Eur Heart J. 2002;(Suppl. 4):D66–D72.
6. Varma S, McElnay JC, Hughes CM. A qualitative assessment of health-related issues of importance in elderly congestive heart failure patients. J Soc Admin Pharm. 2001;18:59–67.
7. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Exploring the spiritual needs of people dying of lung cancer or heart failure: a prospective qualitative interview study of patients and their carers. BMJ. 2002;325:929–33.
8. Rogers A, Addington-Hall JM, McCoy ASM, Edmonds PM, Abery AJ, Coats AJS, Gibbs JSR. A qualitative study of chronic heart failure patients' understanding of their symptoms and drug therapy. Eur J Heart Fail. 2002;4:283–7.
9. Martensson J, Karlsson J, Fridlund B. Male patients with CHF and their conception of the life situation. J Adv Nurs. 1997;25:579–86.
10. Sneed N, Paul S, Michel Y, VanBakel A, Hendrix G. Evaluation of three quality of life measurement tools in patients with chronic heart failure. Heart Lung. 2001;30:332–40.
11. Dracup K, Baker DW, Dunbar SB, Dacey RA, Brooks NH, Johnson JC, Oken C, Massie BM. Management of heart failure. Counselling, education, and lifestyle modifications. JAMA. 1994;272:1442–6.
12. Coats AJS. What causes symptoms in heart failure? Heart. 2001;86:574–8.
13. Hepler CD, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43.
14. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med. 1998;158:1067–72.
15. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of elderly congestive heart failure patients: Interventions and outcomes. Pharmacoth. 1999;19:860–9.
16. Gattis WA, Hasselbad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team — Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study.Arch Intern Med. 1999;159:1939–45.
17. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol. 2000;86:519–23.
18. Pearson GJ, Cooke C, Simmons WKT, Sketris I. Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes. J Clin Pharm Ther. 2001;26:351–61.
19. Stewart S, Marley J, Horowitz J. Effects of a multidisciplinary, home based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomized controlled study. Lancet. 1999;354:1077–83.
20. Gore S. Assessing clinical trials-restricted randomisation. BMJ. 1981;282:2114–7.
21. Cohn SR, Mount MM, Tomas JJ, Mount LF. Existential well-being is an important determinant of quality of life. Cancer. 1996;77:567–86.
22. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331–42.
23. Centre for Health Protection, Department of Health, The Government of HKSAR. Number of Deaths by Leading Causes of Death by Sex by Age in 2011. 2012.
24. Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, et al. Executive summary: HFSA 2010 comprehensive heart failure practive guideline. J Card Fail. 2010;16:475–539.
25. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699–703.
26. Gustafsson F, Arnold JM. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J 2004;25:1596–1604
27. Roberts F, Ryan GJ: The safety of metformin in heart failure. Ann Pharmacother 41:642, 2007.
28. Mariani M, Vella G, Bianchi C, Verde S, De MR, Pirelli S. Implementation of beta-blockade in elderly heart failure patients: role of the nurse specialist. Eur J Cardiovasc Nurs 2008;7:196–203.
29. Lainscak M, Farkas J. Challenges of beta blocker therapy in chronic heart failure: the story continues. Eur J Cardiovasc Nurs 2008;7:159–160.
30. Jaarsma T. Health care professionals in a heart failure team.Eur J Heart Fail 2005;7:343–349.
.png)
